Oncology Progress For BeiGene After Recent Setback
New PD-1 Approval, Data
Despite a recent setback for one commercial product in its oncology portfolio, BeiGene is on a roll with another, receiving the second approval in recent months, and the first in a solid tumor, for tislelizumab. The PD-1 contender has also met its endpoint in a first-line lung cancer trial.
